X4 Pharmaceuticals, Inc (XFOR) stock
XFORNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$2.83−0.29 (-9.29%)
Close on Nov 16, 2026Market cap $280.59MP/E –Yield –
X4 Pharmaceuticals total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
X4 Pharmaceuticals's total debt was $54.57M at Dec 31, 2023. For fiscal 2023 it was $54.57M, up 62.3% from the year before. The highest annual figure on record is $54.57M in fiscal 2023.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $54.57M | +62.3% |
| FY2022 | Dec 31, 2022 | $33.62M | -0.9% |
| FY2021 | Dec 31, 2021 | $33.93M | +2.3% |
| FY2020 | Dec 31, 2020 | $33.18M | +65.9% |
| FY2019 | Dec 31, 2019 | $20.00M | +100.0% |
| FY2018 | Dec 31, 2018 | $10.00M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2023 | Dec 31, 2023 | $54.57M | +273.2% |
| Q2 FY2023 | Jun 30, 2023 | $764.00K | -91.1% |
| Q1 FY2023 | Mar 31, 2023 | $554.00K | -83.8% |
| Q4 FY2022 | Dec 31, 2022 | $33.62M | -0.9% |
| Q3 FY2022 | Sep 30, 2022 | $14.62M | +2009.8% |
| Q2 FY2022 | Jun 30, 2022 | $8.61M | -74.1% |
| Q1 FY2022 | Mar 31, 2022 | $3.42M | -82.9% |
| Q4 FY2021 | Dec 31, 2021 | $33.93M | +69.7% |
| Q3 FY2021 | Sep 30, 2021 | $693.00K | -97.4% |
| Q4 FY2020 | Dec 31, 2020 | $33.18M | +69.7% |
| Q4 FY2019 | Dec 31, 2019 | $20.00M | +100.0% |
| Q3 FY2019 | Sep 30, 2019 | $20.00M | – |
| Q2 FY2019 | Jun 30, 2019 | $26.35M | – |
| Q1 FY2019 | Mar 31, 2019 | $19.55M | – |
| Q4 FY2018 | Dec 31, 2018 | $10.00M | – |
See a number that looks wrong?